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Abstract 
Background: A significant proportion of individuals with REM sleep behavior disorder (RBD) 
will progress to dementia with Lewy bodies (DLB). We aimed to examine whether the APOE ε4 
allele, associated with DLB, is also associated with idiopathic RBD.  
Methods: The two SNPs tagging the different APOE alleles (rs429358 and rs7412) were 
genotyped in individuals who were initially diagnosed with RBD (n=480) and in controls (n=823). 
Results: APOE ε4 allele frequency was 0.14 among RBD patients and 0.13 among controls 
(OR=1.11, 95% CI 0.88-1.40, p=0.41), and this lack of association remained after adjustment for 
age and sex. Furthermore, allele frequencies of APOE ε4 were similar in those who converted to 
DLB (0.14) and those who converted to Parkinson’s disease (0.12) or multiple system atrophy 
(0.14, p=1.0). 
Conclusions: The APOE ε4 allele is neither a risk factor for RBD nor it is associated with 
conversion from RBD to DLB or other synucleinopathies.  
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Introduction 
Rapid eye movement (REM) sleep behavior disorder (RBD), characterized by lack of atonia and 
enacting of dreams during REM sleep, is currently the strongest clinical prodromal feature 
preceding the development of an overt synucleinopathy. In long term follow-up, more than 80% 
of individuals with idiopathic RBD developed either Parkinson’s disease (PD), dementia with 
Lewy bodies (DLB) or multiple system atrophy (MSA).1, 2 It was recently suggested that RBD 
may define a subtype of PD patients,3 further supported by the association of RBD with cognitive 
decline,4 dementia,5 hallucinations6 and autonomic dysfunction,7 as compared to PD patients 
without RBD. In addition, pathological studies in brains of PD patients with and without RBD that 
demonstrated a more widespread α-synuclein accumulation associated with RBD. 
 If indeed RBD represents a subtype of PD, or a subtype of synucleinopathies, it is possible 
that it has specific genetic background. A preliminary study that examined the association of RBD 
with several genetic risk factors for PD, identified an association mainly with MAPT and SCARB2, 
and marginal or lack of association with other markers.8 A recent study suggested that RBD is 
associated with mutations in GBA in both idiopathic RBD and PD cohorts.9 This association was 
stronger than the association of GBA mutations with PD in a similar population,10 suggesting that 
GBA may be one of the genetic factors that is more specific to RBD. Furthermore, the association 
of GBA mutations with DLB11 also seems to be stronger than the association with PD.12 
Conversely, mutations in LRRK2 were not associated with RBD,13-15 further supporting the 
hypothesis that RBD has a distinct genetic background.  
One of the strongest genetic factors associated with DLB is the APOE epsilon4 
(ε4) allele,16 and PD patients who carry this allele may be at increased risk for developing 
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dementia.17  Since both RBD and the APOE ε4 allele are associated with DLB, and with dementia 
in PD patients, we aimed to examine whether the APOE ε4 allele is associated with RBD and 
conversion to DLB.  
 
Methods 
Population 
The study population included consecutively recruited, unrelated idiopathic RBD patients (n=480) 
and controls (n=823) of European ancestry. RBD patients were collected by collaborators from the 
international RBD study group and were diagnosed using polysomnography according to the 
ICSD-2 criteria. The control group was composed of 253 elderly controls (age 59.5±9.8 years, 
matched to the available AAO of RBD, n=307, age 59.2±11.5), 510 young controls (age 34.0±6.5 
years), and additional 60 controls with no available data on age. However, all control groups had 
nearly identical frequencies of the APOE ε4 allele (0.13, 0.13 and 0.14, respectively), suggesting 
lack of age-effect, which allowed us to analyze all controls combined. All individuals signed 
informed consent forms at enrollment, and the study protocols were approved by the respective 
institutional review boards. 
Genotyping 
DNA was extracted using a standard salting-out protocol. To determine the APOE haplotypes, two 
tagging single nucleotide polymorphisms (SNPs), rs429358 and rs7412, were genotyped using 
TaqMan SNP genotyping assays (C___3084793_20 and C____904973_10, respectively, 
ThermoFisher Scientific Inc.) according to the manufacturer's instructions. Genotypes were called 
using the QuantStudio™ 7 Flex Real-Time PCR System and Software (v 1.0). Carriers of T in 
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rs429358 and T in rs7412 were determined as carriers of the ε2 allele, carriers of T in rs429358 
and C in rs7412 were determined as carriers of the ε3 allele, and carriers of C in rs429358 and C 
in rs7412 were determined as carriers of the ε4 allele.   
Statistical analysis 
Categorical variables are presented as percentage or frequencies, whereas continuous variables are 
presented as mean ± standard deviation. Goodness of fit test with one degree of freedom was 
applied to look for deviation from the Hardy-Weinberg equilibrium (HWE) among the controls. 
Differences in APOE allele or carriage frequencies were analyzed using the Fisher’s exact test, 
and differences in continuous variables were analyzed using t-test.  To further avoid a potential 
bias due to age, and since sex distribution was different among patients with RBD vs. controls, a 
logistic regression model with age and sex as covariates was also applied. All statistical analysis 
was done using SPSS statistics V.23 (IBM Inc.). 
 
Results 
Lack of association between the APOE ε4 and RBD risk and age at onset 
Table 1 details the different APOE alleles in RBD patients and controls. The frequency of the two 
SNPs defining the APOE alleles did not deviate from HWE. The allele frequency of APOE ε4 was 
0.14 among RBD patients and 0.13 among controls (OR=1.11, 95% CI 0.88-1.40, p=0.41). 
Overall, 25.8% of RBD patients carried at least one APOE ε4 compared to 23.0% among controls 
(p=0.25, Fisher’s exact test). Logistic regression model adjusted for age and sex also demonstrated 
lack of association between APOE ε4 allele carriage and risk for RBD (OR = 1.25, 95% CI 0.87-
1.79, p=0.23). Data on age at onset (AAO) of RBD was available for 307 individuals, and there 
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was no difference in AAO when comparing carriers (n=88) and non-carriers (n=219) of the APOE 
ε4 allele (59.1 ± 8.4 vs. 59.3 ± 12.6 years, respectively, p=0.92, t-test). 
 
Table 1. APOE haplotypes in individuals with RBD and controls 
APOE ε2/ε2  
n,  
(%) 
ε2/ε3  
n,  
(%) 
ε3/ε3 
n,  
(%) 
ε2/ε4 
n, 
(%) 
ε3/ε4 
n, 
(%) 
ε4/ε4 
n,  
(%) 
Total 
carriers of 
ε4, n (%) 
ε4 allele 
frequency 
RBD patients, 
n=480 
4  
(0.8) 
51  
(10.6) 
301  
(62.7) 
4  
(0.8) 
107  
(22.3) 
13  
(2.7) 
124 
(25.8) 
0.14 
RBD converted to 
synucleinopathya,  
n=140 
3 
(2.1) 
12 
(8.6) 
91 
(65.0) 
1 
(0.7) 
32 
(22.9) 
1 
(0.7) 
34 
(24.3) 
0.13 
RBD not converted 
to synucleinopathyb,  
n=340 
1 
(0.3) 
39 
(11.5) 
210 
(61.8) 
3 
(0.9) 
75 
(22.1) 
12 
(3.5) 
90 
(26.5) 
0.15 
Controls, 
n=823 
5 
(0.6) 
111 
(13.5) 
518 
(62.9) 
14 
(1.7) 
149 
(18.1) 
26 
(3.2) 
189 
(23.0) 
0.13 
n, number; RBD, REM sleep behavior disorder 
a PD, dementia/DLB or MSA 
b including individuals without information on conversion 
 
The APOE ε4 allele is not associated with conversion to PD, DLB or MSA. 
Since most of the patients in our cohort are being followed-up longitudinally, we examined 
whether the APOE ε4 allele is associated with conversion to either PD, dementia/DLB, or MSA. 
A total of 140 RBD patients (29.2%) were reported to have converted to either PD (n=98, 70% of 
the converters), dementia/DLB (n=28, 20%) or MSA (n=14, 10%). The carrier frequencies of one 
or more APOE ε4 in these groups were similar; 23.5%, 25.0% and 28.6%, respectively (p=0.91), 
and the allele frequencies were 0.12, 0.14 and 0.14 (p=1.0). The APOE ε4 allele frequency among 
those that did not convert or whose information was not available was slightly higher, 0.15 (Table 
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1), with a total of 26.5% carriers of at least one APOE ε4 allele, compared to 24.3% among those 
who converted (p=0.65). 
 
Discussion 
Although RBD is a strong risk factor for developing DLB,1, 18 and although DLB was reported to 
be associated with the APOE ε4 allele16, 19, 20, our results demonstrate lack of association between 
the APOE ε4 allele and RBD or its age at onset. These and previous results8, 9, 13, 15 further suggest 
that RBD may have a distinct genetic background; it is associated with GBA mutations, 9 but unlike 
PD it is not associated with LRRK2 mutations,13, 15 and unlike DLB it is not associated with the 
APOE ε4 allele. Thus far, GBA, SCARB2, and potentially SNCA overlap between RBD, PD and 
DLB (Figure 1).8, 9, 21 Whether RBD has additional, unique genetic factors that was not identified 
in PD or DLB cohorts is still to be determined.  
 Since PD patients with RBD are likely to develop dementia and hallucinations,5, 6 
eventually presenting a phenotype similar to DLB, and based on the current and previous genetic 
and post-mortem results,22 we hypothesize that RBD-associated synucleinopathy (the central 
common area in Figure 1) is the same clinical-pathological entity, whether it is defined as 
parkinsonism first with subsequent dementia and hallucinations, or whether it is defined as DLB 
with subsequent parkinsonism. In that sense, RBD can be considered as a marker for diffuse 
synucleinopathy, which may be a better description of the disease than DLB or PD with dementia. 
Neuropathological data from GBA mutations carriers also demonstrated a more diffuse 
synucleinopathy,23-25 further supporting this notion. It is possible that stochastic events, or other 
genetic or environmental factors, determine whether α-synuclein will first be deposited in brain 
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areas associated with dementia and later in the areas associated with parkinsonism, or vice versa. 
The observation that α-synuclein can progress in the brain in a prion-like fashion26-28 may support 
a stochastic progression hypothesis, however additional neuro-pathological studies are needed to 
examine this possibility.  
 The association of RBD with the more devastating synucleinopathy, MSA, also 
necessitates more studies. Whether unique genetic or environmental factors affect the risk to 
progress from RBD to MSA is still unknown. Our current study identified similar frequencies of 
APOE ε4 allele in those who progressed to PD, DLB and MSA, suggesting that APOE is not one 
of these factors. Interestingly, a recent study suggested that GBA mutations are associated with 
MSA as well,29 however this observation is awaiting replications in additional cohorts. 
 Our study has a few limitations. The control population was younger than the RBD and PD 
groups. To tackle this limitation, we took two approaches. First, we demonstrated that the 
frequencies of the APOE ε4 allele were similar across generations (i.e. in the elderly and young 
control groups), which rules out a potential bias. Furthermore, we also performed a logistic 
regression model with adjustment for age, which further demonstrated lack of association between 
the APOE ε4 allele and RBD. Another potential limitations stems from RBD patients being 
recruited in multiple centers, which may lead to a potential population dependent bias, in case one 
or more of these RBD cohorts are enriched in APOE ε4 allele carriers. However, since the 
frequencies of the APOE ε4 allele were similar across centers, this possibility was ruled out.  
 To conclude, our results support a distinct genetic background for RBD-associated 
neurodegeneration, probably suggesting association with isolated synucleinopathy rather than 
tauopathy. To examine the hypotheses raised by the current and previous work, larger studies are 
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necessary, including genome wide association and next-generation sequencing studies focusing on 
RBD, and comparing them to results from PD, DLB and MSA.  
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Tables and Figures. 
Figure 1. Venn diagram of the genetic overlap between PD, DLB and RBD. 
While GBA mutations, SCARB2 and possible SNCA variants are associated with all three 
conditions, other genetic variants such as APOE ε4 in DLB and LRRK2 mutations in PD are 
distinctively associated with each condition but not with RBD. It is therefore likely that RBD-
associated neurodegeneration (the overlapping area of PD, DLB and RBD) may have distinct 
genetic background. While thus far no genetic variants that are uniquely associated with RBD were 
discovered, it is possible that such genetic risk factors do exist, and that they were not discovered 
in PD/DLB studies since RBD cases are diluted within the cohorts used to study these diseases. 
 
 
